KPET Ultra Paceline Corporation (KPET)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | - | - | - | - | - |
| Operating profit | $m | - | |||||||
| Net profit | $m | - | - | - | - | - | - | - | - |
| EPS reported | $ | - | |||||||
| Operating cashflow per share | $ | - | |||||||
| Capex per share | $ | - | |||||||
| FCF per share | $ | - | |||||||
| Free cash flow | $m | - | |||||||
| Net debt | $m | - | |||||||
| Book value equity | $m | - | |||||||
| Book value per share | $ | - | |||||||
| Number of shares | m | - | |||||||
| DPS (TTM paid) | $ | - |
Financial summary
Financials in USDTTM unavailable| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | |||||||
| P/B LTM | x | - | |||||||
| P/S LTM | x | - | |||||||
| P/FCF LTM | x | - | |||||||
| EV/EBITDA LTM | x | - | |||||||
| EV/Sales LTM | x | - | |||||||
| Earnings Yield LTM | % | - | |||||||
| FCF Yield | % | - | |||||||
| Quality | |||||||||
| ROE | % | - | |||||||
| ROIC | % | - | |||||||
| Operating margin | % | - | |||||||
| Gross margin | % | - | |||||||
| FCF/Sales | % | - | |||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | |||||||
| Sales Growth YoY | % | - | |||||||
| Net Income Growth YoY | % | - | |||||||
| FCF Growth | % | - | |||||||
| Operating Profit Growth | % | - | |||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | - | |||||||
| Dividend Growth | % | - | |||||||
| Payout Ratio | % | - | |||||||
| FCF/Debt | x | - | |||||||
| Net Debt/EBITDA | x | - | |||||||
| EBIT/Net interest | x | - | |||||||
| Net debt/market cap | % | - | |||||||
| Net debt/Equity | x | - | |||||||
| Gross debt/equity | x | - | |||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
KPET Ultra Paceline Corporation primarily aims to complete a strategic business combination. This includes initiatives such as mergers, consolidations, share swaps, asset acquisitions, or corporate restructurings involving one or more other enterprises. The company was established in 2025 and operates from Sioux Falls, South Dakota.
Similar companies
- Drugs Made In America Acquisition Corp. Rights
- Averin Capital Acquisition Corp. Units
- Oaktree Acquisition Corp. III Life Sciences
- Blue Acquisition Corp. Unit
- Thayer Ventures Acquisition Corporation II Class A Ordinary Shares
- Research Alliance Corporation III Class A Ordinary Shares
- Blue Acquisition Corp.
- NewHold Investment Corp III
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
KPET Ultra Paceline Corporation (KPET)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
KPET Ultra Paceline Corporation primarily aims to complete a strategic business combination. This includes initiatives such as mergers, consolidations, share swaps, asset acquisitions, or corporate restructurings involving one or more other enterprises. The company was established in 2025 and operates from Sioux Falls, South Dakota.
- Drugs Made In America Acquisition Corp. Rights
- Averin Capital Acquisition Corp. Units
- Oaktree Acquisition Corp. III Life Sciences
- Blue Acquisition Corp. Unit
- Thayer Ventures Acquisition Corporation II Class A Ordinary Shares
- Research Alliance Corporation III Class A Ordinary Shares
- Blue Acquisition Corp.
- NewHold Investment Corp III
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free